Neurocrine Biosciences information

Neurocrine Biosciences, Inc.
Company type	Public company
Traded as	Nasdaq: NBIX; S&P 400 component;
Industry	Biotechnology
Founded	1992; 32 years ago
Headquarters	San Diego, California, U.S.
Key people	William Rastetter, Chairman ; Kevin C. Gorman, CEO
Revenue	US$788 million (2019)
Number of employees	1,350 (June 30, 2023)
Website	neurocrine.com
	Footnotes / references;

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992.^[1] The company is headquartered in San Diego, California, and led by CEO Kevin Gorman.^[3] Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).^[4]

The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia^[5] and with a partner for endometriosis and uterine fibroids.^[6]

^ ^a ^b "Company Overview of Neurocrine Biosciences, Inc". Bloomberg Business. Retrieved May 13, 2018.
^ "Neurocrine Biosciences Revenue 2006-2021 | NBIX".
^ Adams, Ben (August 30, 2016). "Neurocrine Submits Valbenazine NDA Early, Set For 2017 Approval". FierceBiotech. Retrieved May 13, 2017.
^ "FDA Approves New Strength for Tardive Dyskinesia Drug". Pharmacy Times. October 6, 2017. Retrieved May 13, 2018.
^ "Neurocrine Nabs BIAL's PD Therapy Opicapone for North America". Genetic Engineering & Biotechnology News. February 10, 2017. Retrieved May 13, 2018.
^ Cite error: The named reference ela was invoked but never defined (see the help page).

[bb-1] "Company Overview of Neurocrine Biosciences, Inc". Bloomberg Business. Retrieved May 13, 2018.

[2] "Neurocrine Biosciences Revenue 2006-2021 | NBIX".

[ben-3] Adams, Ben (August 30, 2016). "Neurocrine Submits Valbenazine NDA Early, Set For 2017 Approval". FierceBiotech. Retrieved May 13, 2017.

[4] "FDA Approves New Strength for Tardive Dyskinesia Drug". Pharmacy Times. October 6, 2017. Retrieved May 13, 2018.

[gen-5] "Neurocrine Nabs BIAL's PD Therapy Opicapone for North America". Genetic Engineering & Biotechnology News. February 10, 2017. Retrieved May 13, 2018.

[ela-6] Cite error: The named reference ela was invoked but never defined (see the help page).

Neurocrine Biosciences information

and 25 Related for: Neurocrine Biosciences information

Neurocrine Biosciences

Neurocrine

Valbenazine

William Rastetter

Bruker

Concentrix

TKO Group Holdings

List of California companies

Texas Roadhouse

Amkor Technology

Wingstop

Flowserve

Acadia Healthcare

ZoomInfo

Silicon Labs

GXO Logistics

Bank OZK

Indiplon

Five Below

Frost Bank

Planet Fitness

Masimo

Kyndryl

Dynatrace

Skechers